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The pharmaceutical industry was one of the strongest performing sectors of the
Celtic Tiger era. During the past two decades, employment growth in the sector
has been strong and continuous, even when, in recent years, employment in other
manufacturing sectors has been contracting. Although positive in itself, from a
dynamic regional development perspective it is important to explore the
qualitative changes in the types of activities that are conducted in Ireland.
Adopting a global production network approach, the paper examines Ireland’s
changing role in global production networks within the pharmaceutical industry,
focusing on the different components of manufacturing and research and
development (R&D). The analysis shows that Ireland’s involvement in manu-
facturing has shifted in the direction of relatively higher value generating
activities. Within R&D, although the level of value creation has increased
substantially, Ireland’s involvement nonetheless remains concentrated in the
(relatively) lower value generating activities of the global R&D network. In
addition, the sector remains strongly dominated by foreign companies so that a
large share of the created value is not captured within Ireland
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Introduction
The pharmaceutical sector is of substantial importance to Ireland. It accounts for
almost 16% of industrial exports and some 5% of manufacturing employment, and is
one of the highest-skill sectors of manufacturing industry. Yet, the developmental
aspects of the sector have been little researched. This paper provides a detailed
account of the dynamics of the Irish pharmaceutical industry over recent decades.
The paper engages principally with the regional development literature and employs
the Global Production Network (GPN) framework that seeks to shed light on the
relation between economic integration, globalisation and regional development
(Dicken et al. 2001, Yeung et al. 2001, Henderson et al. 2002). This framework
proposes that the globalisation of production networks of firms and institutions
integrates economies in ways which have important implications for development.
We analyse Ireland’s changing role in the global production networks of the
pharmaceutical industry, notably with respect to R&D and manufacturing.
The analysis is based on statistical data from national and international
institutions, on semi-structured face-to-face interviews with senior staff at 12
selected pharmaceutical companies conducted in 20052006 and on an email survey
of all existing pharmaceutical establishments conducted in 2006.
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The semi-structured interviews provided information on the changing role of
Irish subsidiaries in the global production networks of pharmaceutical companies.
The 12 companies selected for detailed study were chosen so as to represent different
countries of origin, different activities (bio-pharmaceutical vs. chemical pharmaceu-
tical) and different geographical locations in Ireland. The sample included US (5),
British (2), Irish (2), Japanese (1), Swiss (1) and French (1) companies. A total of 52
senior staff members were interviewed, including general managers, materials
managers, personal managers and managers of R&D. The aim of the email survey
was to quantify the scale and scope of production process R&D activities in the Irish
industry. Process development managers or managers of technical services in all (80)
pharmaceutical firms were approached and asked to complete a two-page
questionnaire. Seventy six useable questionnaires were returned  a response rate
of 95%. Further detail regarding the survey methodology and response is provided
below (see also van Egeraat 2007).
The paper begins with a discussion of the role of global production networks as
discussed in the regional development literature. This is followed by an account of
the development of the Irish pharmaceutical industry. Following a description of the
value chain of the industry, the paper presents a detailed investigation of the
qualitative changes in Ireland’s role in manufacturing (of both active ingredients and
drug formulations) and various elements of the R&D cycle (including discovery,
clinical trials and process development) and then offers some concluding comments.
Global production networks
Geographers have been active participants in the analysis of regional economic
development. Following the seminal work of Piore and Sabel (1984), many studies
emphasised the role of internal production linkages, local institutions and
indigenous firms. Another body of work has concentrated on external linkages,
notably the impact of subsidiaries of multinational enterprises on local and national
development. Some of the work undertaken in the 1990s assessed the salience of
upgrading processes towards quality/performance plants (Amin et al. 1994),
developmental subsidiaries (Young et al. 1994), and the latter’s developmental
linkages (Turok 1993). Recent work has taken a more dynamic perspective by
analysing the developmental impact of industrial change and the related organisa-
tional dynamics of multinational enterprises (MNEs) (Phelps 1993, Hudson 1994,
Hudson 1997, Pike 1998, Yeung 2000). All of these papers draw on the management
and international business literature on corporate strategy/structure (e.g. Bartlett
and Ghoshal 1989) and subsidiary roles (e.g. White and Poynter 1984, Hedlund and
Rolander 1990, Young et al. 1988).
In searching for an overall framework for understanding issues of global
integration and local economic development, Gerreffi and others developed the
Global Commodity Chain (GCC) framework (Gereffi and Korzeniewicz 1994, Bair
and Gereffi 2001, Gerreffi 2001), which privileges the dynamics of global industries
and the role of external linkages in understanding regional economic development.
Building on the GCC concept, Dicken et al. (2001) propose a Global Production
Network (GPN) framework (see also Yeung et al. 2001, Henderson et al. 2002),
which emphasises the role of the firm and networks of firms. The idea is that
production networks of firms and institutions have become increasingly global and
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integrate economies in ways which have important implications for development. An
understanding of the economic development implications for regions requires a
study of the dynamics of ‘what [lead-] firms do, where they do it, why they do it, why
they are allowed to do it and how they organise the doing of it across different
geographic scales’ (Henderson et al. 2002, p. 5).
Like the GCC framework, the GPN framework acknowledges the importance of
external linkages in seeking to understand the dynamics of local and regional
development. However, the GPN perspective explicitly accords a degree of power
and autonomy to domestic firms, governments and institutions whose actions can
influence the economic outcomes of the network processes in their own locations.
Furthermore, the GPN framework more explicitly acknowledges that inputoutput
flows can be organised horizontally and diagonally as well as vertically. A
particularly appealing aspect of the approach is that it recognises the multi-scalar
nature of GPNs and the forces underlying regional development. Such a view breaks
with the idea of a globallocal dichotomy and allows for the nesting of local clusters
with arguments about globalisation (Sturgeon 2000). In relation to regional
development policy it suggests the need for a favourable ‘strategic coupling’ between
the needs of the various global production networks and the resources and needs of
the region (Coe et al. 2004)
The GPN perspective directs attention to the networks of firms involved in the
whole range of activities linked to a given product (including R&D, design,
production, marketing and other services), the way these are organised globally,
the way this global organisation is influenced by governments and institutions, and
the overall implications for upgrading and development. It provides an elaborate
conceptual framework for linking corporate processes to regional development. One
of the central concepts in the analysis of inter-organisational connections and how
they relate to the economic development of particular localities is value; specifically
the way in which it is created and the extent to which it is captured in various
locations. Part of the contribution of the present paper is to analyse Ireland‘s
changing role in global production networks and what this means in terms of value
creation. Before this, we present an account of Ireland‘s emergence as an important
player in the global pharmaceutical industry.
The growth of the Irish pharmaceutical industry
The development of the Irish pharmaceutical industry has been, and continues to be,
a major international success story. Until the 1960s there was virtually no
pharmaceutical industry in Ireland (Galvin 1998). The post-independence autarkic
economic development policies, including the Control of Manufacturers Act
(designed to keep the ownership of industry in native hands), offered little incentive
for foreign companies to invest in Ireland (White 2000b), while the manufacturing of
most pharmaceutical products was too sophisticated and capital-intensive for
indigenous players. The first substantial investments by foreign pharmaceutical
companies followed rapidly on from the shift towards more outward-looking
economic policies towards the end of the 1950s (van Egeraat 2006, van Egeraat
and Breathnach 2007). However, the sector really took off in the 1970s following the
Industrial Development Authority’s (IDA) adoption of fine chemicals as one of its
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target sectors (Childs 1996). This led to a series of manufacturing investments,
notably by US- and UK-based companies.
Figures 1 and 2 chart the growth of employment in the pharmaceuticals sector in
Ireland in the periods 19791991 and 19912005 respectively, using CSO data. There
is a structural break in the data as the industrial classification system changed in
1991. At the beginning of the period, the sector accounted for around 2500 jobs and
just 1% of manufacturing employment. By 2005, employment numbers in the now
more narrowly defined sector had grown to 11,000 and the sector accounted for 5%
of Irish manufacturing employment. While overall manufacturing employment has
fluctuated over the last decade, recording largely similar numbers for 1995 and 2005,
the pharma sector is one of the few to have recorded almost continuous employment
growth over the period (apart from what might be viewed as a positive upward blip
in 2002).
The Forfa´s employment survey records far higher employment numbers for the
sector than the CSO figures. Using this data set, van Egeraat (2006) shows that in
2003 the industry already employed 19,500 workers (see also Figure 3). Again, the
data paint a picture of strong and nearly continuous employment growth since the
early 1970s  even after 2001, when employment in most other manufacturing sectors
contracted.
The continuing growth of employment in the Irish pharmaceutical industry, even
at a time when employment in other manufacturing industries started to decline has
significantly increased the relative importance of the pharmaceutical industry. Table
1 shows how the share of the pharmaceutical industry in total manufacturing
employment has increased from under 2% in 1990 to 5.2% in 2005, by far the highest
figure for any OECD economy.
The quality of the jobs further increases the importance of the industry.
Pharmaceuticals are by all available measures one of the highest-skill sectors within
Irish manufacturing. Skill intensity is typically proxied either by the share of third-
level graduates in sectoral employment or, more directly, by wage levels per
employee. Table 2 shows that the broad chemicals sector (of which pharma is a
significant component), records the highest skill levels, using the share of third-level
graduates as indicator, while Table 3 shows that this sector, with the lower-tech
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Figure 1. Employment in pharmaceuticals (NACE 257) in Ireland, 19791991.
Source: Census of Industrial Production (various issues)
Note: CIP (1991) yields employment numbers for both NACE 257 and NACE 244 for that
year
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rubber and plastics segment stripped out, records the highest wage levels, although
wages in pharma are marginally below those in the rest of the sector.
Ireland has become an important exporter of pharmaceutical products. Table 4
displays the shares of global pharmaceutical exports recorded for various countries
over the period 19652005. The shares emanating from traditional pharma exporting
countries such as the US, the UK, Switzerland and Germany have all substantially
shrunk. In contrast, Ireland’s market share in pharmaceuticals has grown
substantially, particularly during the Celtic Tiger era and beyond. The expansion
of Ireland’s market share is all the more remarkable in that it has not been replicated
by other non-traditional exporting countries, with the exception of Belgium.
India and China, for example, are yet to become major global exporters of
pharmaceuticals. India’s share of global pharma exports has hovered around 1%
since 1980; while exports by the Chinese pharmaceutical industry are even less
important, accounting for only 0.5% of global exports in 2005. Malaysian and South
Korean pharma exports are also insignificant, while, perhaps surprisingly, Israel and
Singapore hover at around only 1% each.
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Figure 2. Employment in pharmaceuticals (NACE 244) in Ireland, 19912005.
Source: Census of Industrial Production (various issues)
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Figure 3. Pharmaceutical industry employment by sub-sector 19722003.
Source: van Egeraat 2006, based on Forfa´s Employment Survey
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In 2006, Irish pharmaceutical exports were worth around $17 billion. This
accounted for almost 16% of Irish industrial exports and over 6% of world
pharmaceutical exports; while Irish industrial exports overall comprised less than 1%
of world industrial exports. The Irish industry’s growth has been largely based on
foreign direct investment however. In 2003, subsidiaries of foreign companies
accounted for 93% of pharmaceutical employment and virtually all employment in
the drug substance sub-sector. Indigenous operations remained relatively small with
only seven indigenous companies employing more than 50 staff (van Egeraat and
Breathnach 2007).
While pharma imports came to only around $2 billion1, it must be recognised
that a large share of the value of the exports is not added in Ireland. Apart from the
import of raw and intermediate materials, all of Ireland’s foreign-owned manufac-
turing sectors make substantial payments to their overseas parent companies in the
form of royalties and licence fees and payments for miscellaneous business services.
In addition, there is a widespread suspicion that the country’s trade surplus in
pharmaceuticals is inflated by the behaviour of corporations who face an incentive to
shift profits to low-corporation-tax locations such as Ireland. One way in which this
can be done is through the manipulation of ‘transfer prices’ (the prices charged for
the transfer of goods and services between a parent company and its foreign
affiliates).2 Some indications of the possible extent of transfer pricing in the Irish
pharmaceuticals case are suggested by the data in Table 5. Gross value added per
person employed in the sector in Ireland is more than double the EU15 average and
one and a half times the level prevailing in the UK sector; while the share of
Table 1. Share of pharmaceutical sector in manufacturing employment, 19852000, various
countries.
1985 1990 1995 2000 2005
European Union (15 countries) 1.5 1.7 2 2
Belgium 2.1 2.6 3.3
Denmark 2.3 3.1 3.7 2.7
Germany 1.2 1.3 1.6 1.7 1.7
Ireland 1.3 1.9 2.6 3.4 5.2
Greece 2 2.3 2.4 1.7
Spain 1.6 1.6 1.8 1.4 1.5
France 2 2.5 2.7 3 2.8
Italy 2 2.3 1.4 1.5 1.5
Netherlands 1.7 1.6 2
Austria 1.4 2 1.6
Portugal 0.9 0.9 0.8
Finland 0.9 1.5 1.4 1.0
Sweden 1.5 2.2 2.8
United Kingdom 1.3 1.5 2 2.1* 2.1
United States 0.9 1 1.3
Japan 0.9 0.9 1
Source: Eurostat Annual Enterprise Statistics
Note: the 19852000 figures refer only to enterprises employing 20 or more persons
* refers to 2001; blank cells indicate data not available.
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personnel costs in production is substantially lower than in either of the other
geographic entities.3
Profit outflows from Ireland’s FDI-intensive pharmaceutical sector are very
substantial as many foreign parents take substantial dividend payments from their
Irish units (Beesley 2005). Thus, although much value may appear to be created in
Ireland, a large share of this value is not captured in Ireland.
We have seen that the level of economic activity in the Irish pharmaceutical
industry has increased substantially over recent decades and that Ireland has become
one of the main pharmaceutical exporters. The remainder of the paper will analyse in
more detail Ireland’s changing role in the global production networks of the
pharmaceutical industry.
The value chain of the pharmaceutical industry
A basic model of the value chain of the pharmaceutical industry includes the
following segments: discovery, product development or clinical trials, process R&D,
active ingredient manufacturing, drug product (formulation) manufacturing; sales
and marketing; and corporate functions. Discovery covers the initial product R&D
activities, i.e. research into the causes of diseases and the identification of
compounds that have a pharmacological effect. Product development includes the
further development of these compounds, and notably their testing in pre-clinical
and clinical trials. Process R&D is concerned with the development of safe and
efficient manufacturing processes at commercial scale. Manufacturing encompasses
the production of raw materials, intermediates, active ingredients and drug products
(formulations). All these activities are supported by corporate functions such as
strategic and supply chain management and finance.
Table 2. Third-level graduates as share of sectoral employment, 2006.
Third-level graduates
as share of sectoral
employment
Third-level graduates with
degree or higher as share of
sectoral eEmployment
Manufacturing industries 32.8 19.9
Food industries 23.4 14.2
Beverages and tobacco 42.5 27.9
Textiles, clothing, footwear
and leather
18.9 9.9
Wood and wood products 17.3 9.1
Paper, paper products, print-
ing and publishing
35.9 21.8
Chemical, rubber and plastic
products
45.7 31.2
Glass, pottery and cement 18.6 10.0
Metals, metal products, ma-
chinery and engineering
36.6 21.8
Other manufacturing (incl.
transport equipment)
21.6 10.5
Source: Population Census 2006, Volume 10: Education and Qualifications; Table 8.
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The various segments account for different levels of value creation. It is difficult
(and beyond the scope of this paper) to quantify these levels, partly because the
concept is not easy to operationalise.4 One option is to apply the notion of value-
added, which is occasionally employed by the original proponents of the GPN
approach (Henderson et al. 2002, p. 28). Value-added refers to the additional value
of an output over the cost of the inputs used to produce it from the previous stage of
Table 4. Country shares of global pharma exports, 19652005, selected countries.
1965 1970 1975 1980 1985 1990 1995 2000 2005
Ireland 0.6 0.7 1.2 1.2 1.2 2.7 3.2 4.5 6.6
Japan 2.0 2.1 1.6 2.1 2.3 2.5 1.5 2.0 1.0
USA 15.3 13.2 11.5 14.4 16.7 11.9 8.2 11.4 8.7
UK 11.3 10.5 10.8 12.3 11.1 11.5 12.1 11.1 8.6
Switzerland 10.9 10.3 11.0 11.4 9.6 12.4 10.7 9.1 9.0
Italy 3.6 4.8 5.0 4.9 5.1 4.3 4.1 5.9 4.7
France 8.2 7.2 8.3 10.6 9.2 10.4 10.4 10.2 8.8
Germany 27.6 30.7 27.8 16.1 14.2 16.7 14.8 12.7 14.6
Netherlands 8.4 4.4 4.3 4.4 3.6 3.9 5.4 4.1 4.1
Belgium* 1.8 2.6 4.1 4.7 4.0 4.6 7.2 7.4 14
Spain 0.1 0.4 0.5 1.4 1.4 1.8 1.2 1.8 2.5
Source: UN Comtrade database
*Belgium and Luxembourg until 1995; Belgium alone for 2000 and 2005 (Exports from Luxembourg are
insignificant).
Table 3. Wages per head by industrial sector.
Sector 2004 Wages per head, t
Manufacturing industries 32,126
Food beverages and tobacco 31,493
Textiles 23,382
Clothing 22,315
Leather 21,575
Wood and wood products 25,660
Pulp and paper 35,257
Publishing 35,325
Chemicals 39,498
of which: Pharmaceuticals 38,883
Rubber and plastics 27,660
Non-metallic minerals 30,099
Basic and fabricated metals 28,196
Machinery and equipment nec. 29,361
Office machinery and computers 35,714
Electrical machinery 29,805
Radio, TV, and medical devices 31,382
Transport equipment 33,472
Manufacturing nec and fuels 26,407
Source: Census of Industrial Production, Manufacturing Local Units
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production. High value added is generally related to a strong positive impact on
economic development.
Discovery, clinical trials and corporate functions are generally considered to be
high value added activities (Forfa´s 2003). Manufacturing is often seen as a relatively
lower value added activity in pharmaceuticals, although the level of value added in
active ingredients is higher than in drug formulations. Process R&D and sales and
marketing are in turn generally characterised as medium-level. A complementary
way to account for the level of value creation is to consider the skill/education levels
and the number of highly skilled staff involved in pharmaceutical activities and
production in a particular locality.
In reality, as will become clear, most of the segments of the value chain involve a
number of activities with different characteristics in terms of value creation. The
remainder of this paper analyses Ireland’s changing role in global production
networks, focusing on manufacturing of active ingredients and drug formulations,
and R&D in the areas of discovery, clinical trials and process development.
Manufacturing
Pharmaceutical manufacturing includes the manufacture of active ingredients (the
drug substance), drug formulations (the actual tablet, capsule or injection material)
and inputs into these items. Active ingredients, which are responsible for the
pharmacological effect, are the most important ingredients of the drug formulation.
Drug formulation and active ingredients involve different manufacturing processes.
Active ingredients can be manufactured by chemical synthesis, extraction, cell
culture/fermentation or by recovery from natural sources. Chemical synthesis has
long been the most important route, but biotechnology has been growing in
importance as a sub-sector since the 1990s. In drug formulation, the active ingredient
is combined with other inactive ingredients (excipients) in a physical transformation
process involving activities such as granulation, drying, blending and compressing.
The manufacture of active ingredients through chemical synthesis is a multi-stage
process. Chemical ingredients are combined into new molecules in a number of
chemical synthesis steps. The required inputs can be categorised into regulatory
starting materials, basic raw materials and reagents. The regulatory starting
materials are substantial fragments of the active ingredient molecule that are
specified in the process filed with the regulatory authorities. They are specific to the
product and custom made. These are combined with the basic chemicals and
reagents in several chemical transformations. The distinction between active
ingredient and input production is flexible, depending on the number of steps the
pharmaceutical company decides to conduct in house or to outsource. The basic
Table 5. Indications of possible transfer price manipulation in the Irish pharma sector, 2001.
Gross value added per person
employed (thousands of euro)
Share of personnel costs
in production
Industry NACE codes EU15 UK Irl EU15 UK Irl
Pharmaceuticals 24.4 106.3 141.1 251 18.5 20.1 7.2
Source: Barry 2005
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chemicals such as solvents are more general and are used by a variety of industries.
The reagents are speciality chemicals that may be produced for use in particular
types of chemical reaction by a large number of pharmaceutical companies.
The other important route to manufacture active ingredients involves biotech-
nological processes. Advances in biotechnology have made it possible to genetically
manipulate specific bacterial or mammalian cells that produce the required proteins.
The manufacturing process of the active ingredient involves two steps: the growing of
cells in bioreactors (the upstream process) and the subsequent separation/purifica-
tion of the protein (the downstream process). The process involves a more limited
amount of inputs, notably media, buffers and resins. Bio-fermentation is a frontier
technology that typically involves relatively highly skilled personnel.
Figure 3 charts employment growth in different sub-sectors of the pharmaceu-
tical industry in Ireland. It shows that most employment growth was accounted for
by the drug formulations sub-sector (drug products in the diagram) and the relatively
higher value added active ingredients sub-sector (drug substance in the diagram).
Very few companies manufactured other intermediates (van Egeraat 2006).
Active ingredients
The multinational pharmaceutical firms that invested in Ireland in the 1960s and
1970s were models of Fordist industrial organisation that was associated with a
distinct geography of production and R&D (Malecki 1997, Hayter 1998, Dicken
2007). The geography of production was characterised by a decentralisation of
manufacturing functions. Companies established branch plants in numerous markets
to overcome trade barriers and to avail of local tax incentives. Until the 1990s, the
typical active ingredients plant established by foreign pharmaceutical companies in
Ireland was a high volume production plant, producing one or a limited number of
active ingredients for a limited number of formulation plants. Typically a company
would have started producing the product in one of the new-product-introduction
plants, or launch plants, in its home country. The manufacturing process was
typically fully developed and all process issues ironed out before the product was
transferred to a high volume plant in Ireland. The main drivers for investment in
Ireland included low corporation tax and relatively low wages, given that the labour
force was sufficiently skilled. The low rate of corporation tax was particularly
important for the manufacture of high-value active ingredients. Most major pharma
companies invested in at least one overseas high volume active ingredients
production plant in one of only three countries or territories that offered a similar
package of tax and other incentives: Ireland, Puerto Rico or Singapore.
After the 1990s the flow of investment in active pharmaceutical ingredient (API)
manufacturing capacity to Ireland continued unabated. The aggregate growth figures
mask important qualitative changes in Ireland’s role, raising the level of value
creation: notably an increase in launch activities, a focus on the later stages of the
chemical synthesis cycle, and the attainment of global manufacturing mandates. The
growth of biotechnology gave rise to further qualitative changes.
In relation to Ireland’s increasing role in launch activities, it had always made
sense from a taxation perspective to establish launch plants and begin production of
new chemical entities in Ireland. However, launch plants and the related process
development activities require relatively high skills that were not available initially in
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sufficient quantities. This situation changed over the course of the last two decades.
Partly in response to the recognised requirements of the pharmaceutical industry, the
Irish Government invested significant resources to increase the output of graduates
with relevant skills. This allowed for a gradual shift of launch manufacturing (and
related process development activities  see next section) to plants in Ireland. Many
production sites in Ireland became responsible for both new product introductions
and high volume production.
This development coincided with changes in the industry’s technological and
competitive environment. The number of diseases that can be targeted with
chemically derived pharmaceuticals is limited and during the 1990s the number of
potential blockbuster drugs in the pipeline of the traditional pharmaceutical
companies fell sharply. Companies are increasingly relying on smaller volume
high-value drugs for niche markets, and new versions of existing drugs, e.g. for new
indications or variations of conditions. This increased the amount of new product
introductions and the need for ‘flexible’ multi-product launch plants, as opposed to
mono-product plants designed for the synthesis of a specific active ingredient
In addition, in a global context characterised by reduced rates of revenue growth
and increasing costs (see van Egeraat and Breathnach 2008), an increasing number of
companies began to outsource non-core activities. Although the strategies differ,
some companies have started to outsource the early steps of the active ingredient
synthesis cycle. Moving back into the synthesis chain, the regulatory requirements
tend to be lower and, as a result, skill requirements and the required level of control
over the production process diminish. Some companies have outsourced these early
stages to fine chemical suppliers that have been assuming an increased role in the
production of regulatory starting materials. There is some evidence of a spatio-
temporal pattern in outsourcing. At the early stage of the product life cycle,
companies add significant value to the product by using their access to technology to
optimise the production process. Later, when the marginal benefits of further
continuous improvement activities decline and the product moves closer to the end
of its patent-protected period, companies start to outsource the mature product,
thereby also freeing up capacity for new product introductions. Ireland‘s rapidly
rising wage levels during the Celtic Tiger era provided an extra incentive to use the
Irish facilities for the higher value added elements in the manufacturing chain;
notably for new product introductions and late stage synthesis.
Very few processes are outsourced to companies in Ireland. Traditionally the
basic chemicals and fine chemical supplies were imported from suppliers in the UK
and Europe. Over the last decade, however, the pharma companies have increasingly
used low-cost suppliers in India and China, though mainly for lower value added
supplies. The interviews suggest that some pharma companies remain hesitant to
outsource the later stage synthesis to companies in India and China, doubting
whether these companies have the requisite technical knowledge and can meet the
stringent health and safety standards required to supply the highly regulated EU,
Japanese and North American markets. In addition, pharma companies are
concerned that disclosed intellectual property may not be protected. This perception
is changing however and pharma companies have even begun to contemplate setting
up their own API plants in China and India.
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We are now going through an internal discussion. Do we maintain that [production of a
particular product in house] going forward or do we go to India and China and
outsource those products? And we are now starting to do more of that than we have
done in the past. Mainly active ingredients right now [ . . . ] a product that would go off
patent. So we are using some of these compounds as the vehicles to test that
methodology (interview with general manager API plant).
Another qualitative change in Ireland’s role concerns a widening of the manufactur-
ing mandates to cover global markets. Since this development is even more
significant in the context of drug formulation activities, a full discussion will be
included in the next section. The main difference between active ingredients and drug
formulation is that active ingredient plants, given their capital intensive nature, have
always had relatively wide mandates. Geographical strategies are varied and
somewhat idiosyncratic, but it is generally true to say that, until the 1990s, some
of the larger firms tended to organise their active plants on a macro-regional basis,
with the Irish active ingredient plants supplying European formulation plants. Many
of these companies have since adopted a global supply strategy and Irish API plants
have become the single global source for a range of companies’ active ingredients.
Finally, since 2000, Ireland is emerging as an increasingly important location for
biopharmaceutical active ingredient plants (van Egeraat 2006). The rise of
biotechnology, besides introducing a new high-tech production activity to the Irish
pharmaceutical space, has also changed Ireland’s relative role in global manufactur-
ing networks.
Biotechnology is still a frontier science and the production of active ingredients
requires highly skilled staff  even more skilled than in the case of chemical synthesis.
In addition, biofermentation requires a greater process R&D effort, a substantial
amount of which needs to take place at the site of the commercial manufacturing
plant, which further increases skill requirements. By way of illustration, nearly 60%
of all staff at one of the interviewed biopharmaceutical active ingredient plants had
third level degrees. The number of locations that can satisfy these skill requirements
is more limited than in the case of chemical synthesis. In most cases, the Irish facility
is one of only one or two facilities outside a company’s home country, making it a
strategic facility supplying global markets from the start. Although most of the Irish
facilities are established to provide additional capacity for existing products, the
intention is that the plants will begin to act as new product introduction plants as
soon as new molecules emerge from the development pipeline. The technology and
skills requirements mean that at this point in time Ireland competes for inward
investment projects with other technologically advanced locations, including
Switzerland, rather than with low cost economies. ‘At this point in time you would
not be looking at China and India for this type of investment’ (interview with general
manager of biopharmaceutical active ingredient plant). The required inputs mainly
media, buffers and resins  tend to be exclusively sourced from technologically
advanced locations in the USA, Europe and Japan.
Drug formulations
The drug formulations sub-sector has experienced strong growth, particularly since
the 1990s. Here too the absolute growth in formulation activity was accompanied by
important qualitative changes in Ireland’s involvement in global manufacturing
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networks, notably a widening of product mandates to cover European and global
markets. Traditionally, tariff and regulatory non-tariff barriers meant that pharma-
ceutical companies operated separate formulation plants in many different countries
(Jungmittag and Reger 2000). The development of the EU single market and new
WTO agreements led to increasing harmonisation of regulatory regimes and a
reduction of other non-tariff barriers impinging on international trade in pharma-
ceutical products. The expectation was that the development would lead to a global
rationalisation of formulation plants (Howells 1992).
Although we have no global data indicating the extent of this rationalisation, it is
known that several companies comprehensively reorganised their manufacturing
organisation (Forfa´s 1995, EFPIA 2003). These companies concentrated production
in fewer super-manufacturing plants, although even after the rationalisation most
companies still retained a significant amount of formulation plants in different
markets, partly due to the fact that significant non-tariff barriers persisted (White
2000a).
Ireland was strongly positioned to benefit from this trend. First, due to the small
size of its market, Ireland never had had much leverage over pharma companies to
establish small local market-oriented plants. As a result, there were relatively few
small-scale inefficient plants to rationalise and many plants already served export
markets. Secondly, the attractive taxation regime, low labour costs and the presence
of sufficiently skilled labour made Ireland an attractive location for consolidated
manufacturing operations. The classic example in Ireland is the Wyeth Medica plant
in Newbridge. As part of a global restructuring process, this plant was established to
consolidate the formulation activities of 13 manufacturing plants in Europe that had
been closed down. The Irish facility is one of the company‘s two ‘strategic’
formulation plants (the other one is located in Puerto Rico) producing a large
number of products, often for world markets. An indication of the trend towards
global supply mandates is that 31 out of about 80 pharma plants that operated in
Ireland in 2006 were approved to supply the US market (Interview with manager
pharmaceutical division, IDA Ireland 2005; see also McCall 2004).
Besides this widening of the geographical product mandates, some of the
qualitative changes discussed under active ingredients are applicable to formulation
manufacturing, though not always to the same extent. Many formulation plants have
obtained launch plant status and are thus responsible for the relatively skill-intensive
new-product introductions (and related process development activities  see below).
The strategic nature and know-how, in combination with now higher labour costs,
mean that the plants tend to be used for the most value-added markets and stages in
the product life-cycle. Many plants focus on the introduction of new products.
Nearer to patent expiry the same products are outsourced or left to the specialised
generics companies. In addition, the plants in Ireland tend to focus on the more
regulated, more technology intensive, and therefore higher value-added markets,
notably the USA and EU. ‘They [some of the formulation plants in low cost
locations] are low cost operations, serving the local market. They would not have the
capacity or sophistication to supply into Europe or US. For us to supply those small
markets from this plant would be a distraction. Our primary focus is Europe and US’
(interview with general manager, formulation plant).
As to the competition from other locations, while most companies have
production plants in Eastern Europe, India and China to supply the local markets,
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the interviewees still consider these countries substantially less attractive than
Ireland as a location for the formulation of patented drugs for the strongly regulated
markets such as the EU and USA. However, as in the case of active ingredients,
interviewees typically contend that the growing capability in these regions, in
combination with rising costs in Ireland, have the potential to jeopardise Ireland’s
position in the medium term.
Research and development
The Fordist geography of R&D differed from that of production. On an
international level, the R&D functions of multinational companies, particularly
the more strategic activities, remained firmly located in the companies’ home
countries. Some decentralisation of R&D occurred, but such units were typically
small and limited to short-run adaptations of mature products (Hayter 1998). Until
the 1980s, the pharmaceuticals sector followed this locational model closely, with
basic research functions conducted in the central research units located near the head
offices and main production sites of the companies. Branch plants frequently housed
small technical and development units, but the scope of such activities was limited
(Howells 1984). Even in the case of process R&D, the manufacturing process was
typically for the most part developed by the central R&D group located near the
head office and then transferred to the manufacturing function and manufacturing
sites.
This model of R&D involved inherent structural and operational inefficiencies.
Growing competitive and commercial pressures in the post-Fordist period have
forced firms to address these inefficiencies resulting in a significant reconfiguration
of the spatial organisation of R&D. The following sections analyse Ireland’s
changing role in three of the main components of pharmaceutical-industry R&D,
namely discovery, clinical development and process development.
Discovery
The discovery stage is concerned with research into the causes of diseases and the
identification of compounds relevant to particular diseases. A large number of these
leads are assessed for their biological activity. The discovery stage ends with the
selection of one or a small number of drug candidates that are believed to have the
potential for further development.
In the face of renewed competitive pressures and technological change,
pharmaceutical companies have profoundly reorganised their discovery functions.
Although most of the discovery research is still done in the laboratories of the
companies‘ home countries (Agrawall 1999), discovery activities have become truly
international. In addition, firms increasingly rely on external sources of knowledge,
notably dedicated biotechnology firms. Apart from the establishment of overseas
R&D laboratories, the internationalisation process takes many other routes such as
the establishment of alliances and joint ventures between large pharmaceutical
companies, R&D co-operation and licensing agreements with dedicated biotechnol-
ogy firms, pre-competitive research collaboration with universities, and the financing
of university research (Reger 2000). As regards their internal R&D activities, most
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large pharmaceutical companies have now created globally integrated networks of
research units, often specialised in a particular disease or technology (centres of
excellence). Although strongly internationalised, the discovery research units are
highly concentrated in a relatively small number of countries (Taggart 1993,
Schweitzer 1997, Lane and Probert 2005) and, within these, in a small number of
global ‘megacentres’ that offer important pools of specialised skills and facilitate
knowledge exchange (Cooke 2005, Zeller 2004).
The internationalisation of discovery has largely bypassed Ireland. In 1999, there
was little or no drug discovery conducted in Ireland (ICSTI 1999) and this situation
has changed little. None of the 11 multinational companies interviewed for this
research had a formally constituted discovery laboratory in Ireland. All companies
had multiple discovery laboratories in several countries. All had one or more
discovery laboratories in the USA, while eight had at least one laboratory in the UK.
The main second tier locations included Switzerland (3 companies), France (3) and
Spain (3).
The IDA never targeted the large-scale discovery laboratories. It was not
considered a realistic option because, until recently, the relevant science and
technological infrastructure in Ireland was poor by international standards. In
1999 there were no world class universities or centres of excellence and university
industry co-operation was superficial, short-term and under-funded (ICSTI 1999).
This situation has changed profoundly since 2000 when the Irish Government started
to invest heavily in the national science and technology infrastructure. Science
Foundation Ireland has funded a large body of academic researchers and research
teams involved in basic research, notably in the field of biotechnology. These
developments are unlikely to be sufficient to attract large scale discovery units of
multinational companie, however, as the pharmaceutical companies interviewed
continued to rate the chance of their companies establishing discovery functions in
Ireland as low or very low.
Although not sufficient to attract large scale discovery units of multinational
companies, the upgraded science base has increased Ireland’s role in the inter-
nationalised discovery networks of the pharmaceutical industry in an indirect way.
Through the SFI-funded universityindustry collaborations known as Centres of
Science Engineering and Technology (CSETs), several Irish universities are now
directly co-operating with international pharmaceutical companies in basic research
projects. In addition, more recently, the IDA has recognised that the upgraded
technology base provides a new opportunity for attracting foreign investment in
applied research, and a small number of multinational pharmaceutical companies
are now directly employing staff, integrated in applied research groups at Irish
universities. Finally, the growing body of Irish scientists, in combination with start-
up funding provided by Enterprise Ireland, has resulted in the growth of indigenous
campus and start-up companies in the area of pharmaceuticals and biotechnology. A
small number of these research-focused companies have established collaboration
agreements with major pharmaceutical companies. Although these developments are
encouraging, the number of start-up companies that have brought products to
clinical trials stage is small, and Ireland’s involvement in drug discovery in general
remains limited by international standards.
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Clinical trials
Clinical studies involve the testing and evaluation of new drug candidates on human
subjects in randomised controlled trials. The core activities include the collection,
management and analysis of highly codified clinical data as well as project
management and support. Due to increasingly stringent regulatory requirements,
clinical studies can now take between 6 and 10 years, depending on the therapeutic
area, and have become the greatest cost factor in bringing a new drug to market
(Chiesa 1996, Reger 2000, Schofield 2001).
The clinical trials process is typically organised through a three-tiered structure.
The product team within the pharmaceutical firm integrates the trial results into the
drug development plan. Secondly, the clinical monitors project/manage the trials and
oversee the quality of the data. Clinical monitoring mainly concerns the routine
manipulation, storage, and transfer of codified data, though the monitors also have a
role in problem identification and mediating disputes. Finally, the group of clinical
investigators enrol patients into the study and oversee test patients at the clinic
(Azoulay 2003).
A large part of the actual data collection activity takes place in a variety of clinics
whose work is financed by the pharmaceutical companies. Many hospitals have
developed dedicated centres to facilitate clinical trials work. The clinical monitoring
activities were traditionally conducted by the pharmaceutical companies‘ clinical
operations groups, and large companies continue to operate a number of clinical
research units located in different parts of the world. However, since the 1980s, the
monitoring and data management activities have been increasingly outsourced to
specialised Clinical Research Organisations (CROs). These CROs are typically
involved in the operational aspects of the study with little or no input into the more
knowledge-intensive elements of the monitoring activities. As such, the CROs have
been characterised as ‘data sweatshops’, and their employees as ‘data mules’.
(Azoulay 2003).
Clinical trials have been identified as an important opportunity to increase
Ireland’s involvement in high value added activities in the pharmaceutical industry,
(Forfa´s 2003, ICSTI 2003, Enterprise Strategy Group 2004) and IDA Ireland is
specifically targeting this segment. Recently, a number of universities established the
Irish Clinical Research Network in an attempt to fill the gaps in Ireland’s clinical
research infrastructure. Until now the efforts have had limited success and clinical
trials remain under-represented in Ireland (Forfa´s 2003, Brennan 2008). Apart from
the dedicated clinical research centres connected to major hospitals (Beaumont, St.
James, Vincent’s), direct investment by the private sector has been extremely limited.
Exceptions include the clinical research unit of Merck in Dublin and a small number
of subsidiaries of international CROs, notably Quintiles.
A number of factors are important in a company’s location decision for clinical
trials, inter alia: the importance of the market for the drug; a high willingness and
ability to cooperate on the part of professional clinics and doctors; strong
cooperation with the national approval authorities; efficiency of the ethics commis-
sions involved; and costs, quality and time performance (Reger 2000). The creation of
a pan-European clinical research market and unified legal environment (Samsonov
2005) have to some extent reduced Ireland’s disadvantage in terms of market size;
although the increasingly important pan-European regulatory authorities are located
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outside Ireland (Reger 2000). However, according to one interviewee at a clinical trials
unit, a new obstacle for Ireland is that it has become increasingly difficult and
expensive to recruit test volunteers.
Process R&D
After the identification of a new target molecule in product development, process
R&D is responsible for the development of safe and efficient manufacturing
processes of commercial scale. The process R&D cycle of the pharmaceutical
industry is complex and involves a number of integrated activities. The various stages
of the cycle are listed in Table 6, starting with pre-formulation studies and ending
with continuous improvement and the development of generation processes. A
detailed discussion of the various activities is beyond the scope of the present paper.
For the present discussion it is important to point out that, although all stages can
involve skilled and highly educated staff, the early stages in the cycle involve the
greatest number of and the most highly skilled researchers. In addition, companies
generally aim to have made most major decisions regarding the process prior to
phase III clinical trials (activity 7 and 8 in Table 6). From here on, process
development focuses on the final details of the process.
Until the mid-1980s, under the Fordist regime, branch plants frequently housed
small technical and development units that had some role in process development,
but the scope of such activities was limited (Howells 1984). Typically, the
Table 6. Involvement of Irish establishments in process R&D activities.
Likert scale score
(% of establishments)*
Process R&D activities 1 2 3 4 5 6 7 mean
1 Pre-formulation studies. 74.6 6.8 0.0 1.7 5.1 3.4 8.5 2.0
2 Derivation of initial route/process options
and preliminary evaluation
71.0 11.3 1.6 3.2 6.5 1.6 4.8 1.9
3 Evaluation in small scale experiments 63.9 13.1 3.3 3.3 4.9 1.6 9.8 2.2
4 Evaluation in kilo lab 62.1 10.3 5.2 1.7 5.2 6.9 8.6 2.3
5 Production for Phase II clinical trials 52.8 13.2 5.7 5.7 7.5 1.9 13.2 2.6
6 Evaluation and optimisation in pilot plant
prior to Phase III clinical trials
39.6 17.0 17.0 7.5 5.7 5.7 7.5 2.7
7 Production for Phase III clinical trials 25.9 5.6 9.3 9.3 14.8 16.7 18.5 4.1
8 Evaluation and optimisation in pilot plant
during Phase III clinical trials
27.8 9.3 14.8 7.4 16.7 13.0 11.1 3.6
9 Equipment design 9.7 9.7 11.3 14.5 19.4 19.4 16.1 4.5
10 Optimisation in commercial plant (pre
filing)
4.8 3.2 3.2 6.5 16.1 21.0 45.2 5.7
11 Validation 0.0 0.0 3.2 4.8 6.5 22.6 62.9 6.4
12 Continuous improvement 0.0 1.6 0.0 1.6 9.7 21.0 66.1 6.5
13 Development of second generation process
(outside filing parameters)
9.8 8.2 14.8 4.9 14.8 11.5 36.1 4.9
*Note: 1no input in activity by Irish plant; 7Irish plant has sole ownership of activity.
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manufacturing process was for the most part developed by the central R&D group
located near the head office and then transferred to the manufacturing sites.
The results of the email survey of all pharmaceutical companies in Ireland show
that the role of Ireland in the global process R&D networks of multinational
pharmaceutical companies has changed since the mid-1980s (see also van Egeraat
(2007). In the period 20002006, the number of people involved in process R&D
almost doubled, from 408 to 800, compared with a 36% growth rate in total
employment over the period.
To get an insight into the relative role of the Irish plants in the global networks of
their parent firms, survey respondents were asked to rate the input of the local staff
in various process R&D activities of the parent firm on a seven-point Likert scale
(where a score of 1 indicated that the Irish plant had no input in the activity and a
score of 7 indicated that the Irish plant had sole ownership of the activity in
question). The findings of this question are presented in Table 6. The columns
represent the proportion of relevant establishments falling into each Likert scale
score category while the ‘mean’ column indicates the mean score obtained for all
respondent establishments for the relevant R&D activity
Although there are important differences between individual companies, the data
clearly show that the involvement of the Irish staff in process R&D only becomes
substantial after the proof-of-concept point, at the beginning of phase III clinical
trials.5 As mentioned earlier, this is the point at which companies generally want to
have locked down the process parameters. From here on, process R&D activities
focus on the final details of the process and technology transfer. The fact that the
Irish establishments tend to concentrate their involvement in process R&D activities
in the later stages of the cycle does not mean that they are involved in low-skilled or
mundane activities. The education profile of staff involved in process R&D can be
used as an indicator of the quality or sophistication of the activities carried out in the
Irish subsidiaries. The survey shows that process R&D activities in the Irish
pharmaceutical sector employ a substantial number of highly skilled people, with
30% of the 800 people involved holding a PhD degree as their highest level of
academic attainment, with 19% having a Master’s degree, and a further 46% holding
a primary degree.
The change in Ireland’s role in process R&D activities is the result of several
partly integrated drivers (van Egeraat and Breathnach 2008). First, reacting to
increasing costs of developing new products alongside pressure on drug prices and
revenues, pharmaceutical companies have begun to organise their process develop-
ment function more effectively. The required co-ordination between the various
stages of the process development cycle and between process development and
manufacturing functions has been achieved by co-locating selected process R&D
functions at manufacturing plants, including in Ireland. Another important driver
lies in the international taxation regime, notably the introduction in the mid-1990s of
US legislation for cost-sharing arrangements for developing intellectual property.
This provided an instrument for US multinationals to share the costs of developing
intellectual profits between various subsidiaries, and thereby shifting some of the
profits to subsidiaries in lower-tax jurisdictions, including Ireland. The location in
Ireland of functions additional to manufacturing, notably R&D pilot plants, could
be used to justify higher levels of value added and profits attributed to the Irish
subsidiaries. Finally, a number of measures implemented by the Irish Government in
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recent years have also exerted a positive influence on the disposition of pharmaceu-
tical MNEs towards locating process R&D activities in Ireland without necessarily
being a key driver, namely: the investment in education and the resulting rapid
growth in the supply of science and technology graduates discussed earlier; the major
expansion of state funding of scientific research; tax credits for R&D expenditure
and grant schemes to support R&D initiatives.
Conclusion
Mainly driven by foreign direct investment, employment and export levels of the
Irish pharmaceutical industry have grown substantially over recent decades, and
Ireland has become one of the main pharmaceutical exporters. The growth
continued after 2002, at a time when most other manufacturing sectors in Ireland
experienced decline. This growth is positive in itself, particularly in light of the fact
that the pharmaceutical sector is one of the most skill-intensive manufacturing
sectors in Ireland. From a dynamic regional development perspective it is also
interesting to explore the qualitative changes in the types of activities that are
conducted in Ireland. Adopting a global production network approach for
examining regional development in the context of globalisation, the paper examined
Ireland’s changing role in global production networks within the pharmaceutical
industry, focusing on the different components of manufacturing (i.e. active
ingredients and drug formulations) and R&D (i.e. discovery, clinical trials and
process development).
Within manufacturing, there has been very little growth in the (relatively) low
value generating activity of basic chemicals. Employment growth instead occurred
mainly in drug formulation and the higher-value-generating active ingredients sub-
sector. Alongside this, Irish plants have assumed a greater role in launch activities, an
increased focus on the later stages of the chemical synthesis cycle, and a geographical
widening of product mandates. All these developments have substantially increased
the level of value creation. A similar evolution is apparent in certain segments of the
computer hardware sector and in computer services (van Egeraat and Jacobson
2004, Barry and van Egeraat 2008).
Ireland’s role in pharmaceutical R&D differs considerably from activity to
activity. Notwithstanding recent developments in Irish third-level institutions and
the growing number of indigenous research-based companies, Ireland’s relative role
in the high value generating drug discovery field remains very limited. Similarly, in
spite of efforts to upgrade the necessary infrastructure, high value generating clinical
trials activities remain under-represented in Ireland. Finally, Ireland’s role in the
medium value generating process R&D activities has increased substantially, with a
doubling of the number of people involved over the period 20002006. Even in this
area however, Ireland’s involvement is concentrated in the (relatively) lower value
generating down-stream phases of the cycle.
Although the picture is complex and differentiated, the level of value creation in
the Irish pharmaceutical industry has increased substantially over the Celtic Tiger
era. In spite of an increasing number of indigenous research-focused start-up
companies however, the sector remains strongly dominated by foreign investment so
that a large share of the value created is not captured within Ireland.
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Notes
1. Data from intracen.org (the International Trade Centre, a joint facility of UNCTAD and
the WTO).
2. As Desai et al. (2006) point out, ‘OECD governments require firms to use transfer prices
that would be paid by unrelated parties, but enforcement is difficult, particularly when
pricing issues concern differentiated or proprietary items such as patent rights. Given the
looseness of the resulting legal restrictions, it is entirely possible for firms to adjust transfer
prices in a tax-sensitive fashion without violating any laws.’
3. Stewart (1989) provides further evidence indicative of such practices.
4. Henderson et al. 2002, for example define value as ‘a combination of the Marxian notion of
surplus value with more orthodox notions of economic rent’.
5. A detailed analysis of the differences between companies is beyond the scope of this article
but it is interesting to note one example related to national culture. Corporate strategy
towards the management of global production networks and the level of internationalisa-
tion of R&D is believed to be strongly related to the nationality of the lead firm (Dicken
2007). The detailed case study of a Japanese pharmaceutical firm suggests that the
particular spatial configuration and organisational co-ordination at this firm is indeed
related to culture. The technical support group at this Japanese facility has a very limited
role in process R&D. The technology transfer is carried out by staff flown in from Japan. ‘It
is not a consultative process, let’s put it that way. ( . . . ) I worked for a Japanese and
American company and they both have very different ways of doing tech transfer. ( . . .) If
you look at European or American subsidiaries, they have a lot more autonomy and there
is a lot more expected of them and I think in Japanese companies, knowledge is key and the
retention of knowledge is paramount to a certain extent. So, I am not sure how much really
they are going to give over. I think it is very much a cultural thing.’ (Manager, technical
support unit, Japanese pharmaceutical plant)
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